Cue Biopharma, Inc. (CUE): R&D Expense
$37.74M
Year ended 2025-12-31
$77.19M
Trailing 12 months to 2026-06-30
-0.7%
3-year compound annual growth
+2.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.74M | +4.0% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $36.30M | -11.0% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $40.80M | +5.8% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $38.58M | -6.7% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $41.35M | +23.3% | 2023-03-21, From 2021-01-01 |
| 2020-12-31 | $33.55M | +22.0% | 2022-03-16, From 2020-01-01 |
| 2019-12-31 | $27.49M | -3.7% | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | $28.54M | +51.0% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $18.90M | n/a | 2019-03-14, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $37.74M | +4.0% |
| Celularity Inc (CELU) | 2025-12-31 | $15.03M | -13.6% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $142.27M | +13.5% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $85.47M | -9.6% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $114.60M | +40.9% |
| Alumis Inc. (ALMS) | 2025-12-31 | $386.00M | +45.4% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $7.17M | -1.4% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $141.83M | -6.3% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $8.86M | -25.2% |
Compare CUE, CELU, TRDA, FHTX side by side · Screen every company in Pharmaceutical Preparations ↗